Short answer
OmniAb, Inc. (OABI) filed an 8-K current report with the SEC on October 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). OmniAb reported financial results for Q3 and nine months ended September 30, 2026.
OmniAb, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- OmniAb reported financial results for Q3 and nine months ended September 30, 2026
- Exhibit 99.1 contains the substantive earnings release and financial details
- Results furnished under Regulation FD, generally not subject to Section 18 filing liability
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue rose to $4.0M from $2.2M, while net loss narrowed to $15.7M from $16.5M
- Nine-month revenue reached $31.8M versus $10.3M, driven primarily by $21.6M in license and milestone revenue
- 2026 revenue guidance increased to $35M-$39M, with year-end cash outlook raised to $53M-$57M
- Eli Lilly collaboration adds up to $370M in potential milestones plus tiered royalties for a new ion channel program
- xPloration broader launch targets an estimated market above $500M, with revenue expected at $2M-$3M in 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other OmniAb, Inc. 8-K filings
Get the next OABI 8-K as it lands
Follow OABI for push alerts, or ask the research agent what this filing means.